Gene · 3455
IFNAR2: interferon alpha and beta receptor subunit 2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. IFNAR2: interferon alpha and beta receptor subunit 2. Genes, record 3455. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/3455
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P48551 | Interferon alpha/beta receptor 2 | 515 | 9 | Ensembl, GeneID, HGNC |
Source UniProt
Patents83
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| WO 2026117686 A1 | 2026-06-04 | 25 | P48551 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 50035 | P48551 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 50036 | P48551 | Espacenet |
| WO 2025247913 A1 | 2025-12-04 | 2 | P48551 | Espacenet |
| WO 2025247917 A1 | 2025-12-04 | 2 | P48551 | Espacenet |
| WO 2025247918 A1 | 2025-12-04 | 2 | P48551 | Espacenet |
| WO 2025247924 A1 | 2025-12-04 | 2 | P48551 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 6859 | P48551 | Espacenet |
| EP 4633648 A1 | 2025-10-22 | 48 | P48551 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 17018 | P48551 | Espacenet |
1 to 10 of 83
See all 83 patentsDrugs11
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ALBINTERFERON ALFA-2B | CHEMBL2107842 | Interferon alpha/beta receptor agonist | AGONIST | ChEMBL |
| INTERFERON ALFA-2A | CHEMBL2108508 | Interferon alpha/beta receptor agonist | AGONIST | ChEMBL |
| INTERFERON ALFA-2B | CHEMBL1201558 | Interferon alpha/beta receptor agonist | AGONIST | ChEMBL |
| INTERFERON ALFA-N3 | CHEMBL2109047 | Interferon alpha/beta receptor agonist | AGONIST | ChEMBL |
| INTERFERON ALFACON-1 | CHEMBL1201557 | Interferon alpha/beta receptor agonist | AGONIST | ChEMBL |
| INTERFERON BETA-1A | CHEMBL1201562 | Interferon alpha/beta receptor agonist | AGONIST | ChEMBL |
| INTERFERON BETA-1B | CHEMBL1201563 | Interferon alpha/beta receptor agonist | AGONIST | ChEMBL |
| PEGINTERFERON ALFA-2A | CHEMBL1201560 | Interferon alpha/beta receptor agonist | AGONIST | ChEMBL |
| PEGINTERFERON ALFA-2B | CHEMBL1201561 | Interferon alpha/beta receptor agonist | AGONIST | ChEMBL |
| PEGINTERFERON BETA-1A | CHEMBL2108677 | Interferon alpha/beta receptor agonist | AGONIST | ChEMBL |
1 to 10 of 11
See all 11 drugsTrials1,349
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07553767 | INTERFERON ALFA-2B | EARLY_PHASE1 | ClinicalTrials.gov | |
| NCT07537387 | PEGINTERFERON ALFA-2A | ClinicalTrials.gov | ||
| NCT07521046 | ROPEGINTERFERON ALFA-2B | PHASE1 | ClinicalTrials.gov | |
| NCT07468916 | ROPEGINTERFERON ALFA-2B | PHASE2 | ClinicalTrials.gov | |
| NCT07445893 | INTERFERON ALFA-2B | ClinicalTrials.gov | ||
| NCT07445893 | PEGINTERFERON ALFA-2B | ClinicalTrials.gov | ||
| NCT07307586 | INTERFERON ALFA-2A | PHASE3 | ClinicalTrials.gov | |
| NCT07288112 | PEGINTERFERON ALFA-2A | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07282132 | ROPEGINTERFERON ALFA-2B | ClinicalTrials.gov | ||
| NCT07269470 | ROPEGINTERFERON ALFA-2B | PHASE2 | ClinicalTrials.gov |
1 to 10 of 1,349
See all 1,349 trialsNIH grants2,761
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | IFNAR2 papers | Newest fiscal year |
|---|---|---|---|
| UL1TR001866 | Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational Success | 45 | 2025 |
| R01AI163029 | Inborn errors of immunity in patients with life-threatening COVID-19 | 21 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 15 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 13 | 2025 |
| ZIAAI001265 | Host factors contributing to susceptibility to COVID-19 disease | 11 | 2025 |
| R01AI127564 | Genome-wide search for inborn errors of IL-17 immunity underlying chronic mucocutaneous candidiasis | 10 | 2025 |
| P30CA046934 | University of Colorado Cancer Center Support Grant | 9 | 2025 |
| ZIAAI001270 | Characterization of host immune responses to SARS-CoV-2 | 9 | 2025 |
| R01AI051321 | Structure-based engineering of immune cytokine signaling | 8 | 2025 |
| P30CA016042 | Cancer Center Support Grant | 7 | 2025 |
1 to 10 of 2,761Source NIH's project files
See all 2,761 nih grantsPapers3,850
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Host Genetic Susceptibility and Antiviral Immunity Shape the Pathogenesis and Outcomes of Herpes Simplex Encephalitis. | Biology (Basel) | 2026 | 42792593 | PubTator, text mining | PubMed |
| Functional divergence of the Bhanja virus NSs protein modulates interferon antagonism and viral fitness across divergent lineages. | PLoS Pathog | 2026 | 42784634 | PubTator, text mining | PubMed |
| Functional diversity of natural human IFNB1 variants in innate immunity. | Sci Adv | 2026 | 42758835 | PubTator, text mining | PubMed |
| TLR7/9 and type I interferon signaling reprogram neutrophil NET responses and impair antibacterial defense in systemic lupus erythematosus. | Cell Press Blue | 2026 | 42746563 | PubTator, text mining | PubMed |
| Integrated Inflammatory, Thrombo-Inflammatory, Redox and Soluble IFNAR2 Profiling During Hospitalization for COVID-19: An Exploratory Observational Cohort Study. | J Clin Med | 2026 | 42739730 | PubTator, text mining | PubMed |
| Transcriptomic profiling reveals immune signatures associated with potential COVID-19 susceptibility and a predictive framework in a Chinese cohort. | Front Immunol | 2026 | 42698521 | PubTator, text mining | PubMed |
| Regulators of interferon-responsive microglia uncovered by Genome-wide CRISPRi screening. | NPJ Dement | 2026 | 42694111 | PubTator, text mining | PubMed |
| IL-17A Restrains Antiviral Immunity to Promote Chikungunya Virus Infection and Pathogenesis in the Heart. | bioRxiv | 2026 | 42620426 | PubTator, text mining | PubMed |
| Developing and Characterizing a Murine Model of In Utero Transmission of Ebola Virus. | bioRxiv | 2026 | 42620007 | PubTator, text mining | PubMed |
| Disentangling Shared and Differential Genetic Architectures Between COVID-19 and Other Respiratory Disorders-A Genome-Wide Multi-Omics Framework. | Int J Mol Sci | 2026 | 42511876 | PubTator, text mining | PubMed |
1 to 10 of 3,850
See all 3,850 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/3455
GET https://conductscience.org/api/genes/v1/3455/patents?page=2